Abstract P2-12-18: A Randomized Phase 2 Non-inferiority Trial of (Z)-endoxifen and Exemestane + Goserelin as Neoadjuvant Treatment for Premenopausal Women with ER+/HER2-Breast Cancer (EVANGELINE)
Matthew Bidwell Goetz(University of California, Los Angeles), Steven C. Quay(Aptevo Therapeutics (United states)), Pooja Advani(Jacksonville College), Sarah A. Buhrow(Mayo Clinic), Amy C. Degnim(Mayo Clinic in Arizona), Daniel Flora(St. Elizabeth Healthcare), Felipe Batalini(Beth Israel Deaconess Medical Center), Joel M. Reid(Children's Hospital of Philadelphia), Jason M. Jones, Judy C. Boughey(Mayo Clinic in Arizona), John R. Hawse(Mayo Clinic in Arizona), Katie N. Hunt(Mayo Clinic), Nusayba A. Bagegni(Washington University in St. Louis), James W. Jakub(Mayo Clinic in Arizona), Roberto A. Leon‐Ferre(Mayo Clinic), Lida A. Mina(Mayo Clinic in Arizona), Mara A. Piltin(Mayo Clinic), Vera J. Suman(Mayo Clinic in Arizona), James N. Ingle(Mayo Clinic), Karthik V. Giridhar(WinnMed), Harjinder Singh, Sandra S. Hammer, Arezoo Mirad, Matthew J. Schellenberg(Mayo Clinic)
Cited by 0
Related Papers
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer
|Clinical Cancer Research|2013|744